Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review.
Patient safety is a primary priority in the conduction of retinal gene therapy trials. An understanding of risk factors and mitigation strategies for post-procedure complications is crucial for the optimization of gene therapy clinical trial protocols. In this review, we synthesize the literature on ocular delivery methods, vector platforms, and treatment-emergent adverse effects in recent gene therapy clinical trials for inherited retinal diseases.
['Nuzbrokh|Yan|Y|', 'Kassotis|Alexis S|AS|', 'Ragi|Sara D|SD|', 'Jauregui|Ruben|R|', 'Tsang|Stephen H|SH|']
Adverse events Inherited retinal diseases Retinal gene therapy